An advanced lipid panel is a blood test that goes beyond the four standard cholesterol numbers to measure the size, number, and type of cholesterol-carrying particles in your blood. A standard lipid panel tells you how much cholesterol you have. An advanced panel tells you more about the particles delivering that cholesterol, which can reveal cardiovascular risk that standard numbers miss entirely.
How It Differs From a Standard Lipid Panel
A standard lipid panel measures four things: total cholesterol, LDL cholesterol (often called “bad” cholesterol), HDL cholesterol (“good” cholesterol), and triglycerides. These are reported as concentrations of cholesterol in your blood, measured in milligrams per deciliter. For most people, these numbers provide a reasonable picture of heart disease risk.
An advanced panel keeps all of those standard measurements but adds several more. The exact markers vary by lab, but the most common additions include LDL particle number, LDL particle size, apolipoprotein B, lipoprotein(a), and sometimes inflammatory markers like high-sensitivity C-reactive protein. Together, these extra markers help distinguish between people whose standard numbers look similar but whose actual risk levels are very different.
Why Particle Number Matters More Than Cholesterol Level
Here’s the core idea behind advanced testing: cholesterol doesn’t float freely in your blood. It travels inside particles, like passengers in cars. A standard panel counts passengers (cholesterol). An advanced panel counts cars (particles). Two people can have the same amount of LDL cholesterol but very different numbers of LDL particles carrying it.
This mismatch, called discordance, is surprisingly common. In a large study published in the Journal of Clinical Lipidology, roughly half of participants had discordant LDL cholesterol and LDL particle numbers, meaning the two measurements pointed in different directions. Among those discordant individuals, LDL cholesterol was essentially useless for predicting heart disease events (no statistically significant association). LDL particle number, on the other hand, remained a strong predictor of cardiovascular events regardless of whether the two measurements agreed or not.
This matters most for people with metabolic syndrome, insulin resistance, or type 2 diabetes. These conditions tend to produce smaller, denser LDL particles that carry less cholesterol per particle. Your LDL cholesterol number can look normal or even good while the actual number of atherogenic particles circulating in your blood is dangerously high.
Key Markers on an Advanced Panel
LDL Particle Number (LDL-P)
This is a direct count of LDL particles in your blood, typically reported in nanomoles per liter. It’s one of the most clinically useful additions because it captures risk that LDL cholesterol can miss. When particle number and cholesterol level disagree, particle number is the better guide to actual risk.
LDL Particle Size
LDL particles come in a range of sizes. Small, dense particles are considered more dangerous than large, buoyant ones for specific reasons: they slip into artery walls more easily, they’re more prone to the chemical changes (oxidation) that trigger plaque formation, and they’re cleared from the bloodstream less efficiently because they don’t bind as well to the receptors that normally pull LDL out of circulation. Having a predominance of small, dense LDL particles is sometimes called “Pattern B” and is associated with higher cardiovascular risk.
Apolipoprotein B (ApoB)
Every LDL particle, and every other artery-clogging lipoprotein, carries exactly one molecule of a protein called apolipoprotein B on its surface. That makes ApoB a simple, direct count of all atherogenic particles in your blood, not just LDL but also other harmful types. Atherosclerosis is more closely tied to the number of these particles than to the amount of cholesterol they carry. Clinical trials of cholesterol-lowering medications have consistently shown that ApoB levels predict coronary heart disease more accurately than LDL cholesterol or non-HDL cholesterol.
European cardiovascular guidelines now include specific ApoB treatment targets. For people at high cardiovascular risk, those guidelines recommend an ApoB level below 80 mg/dL, though recent U.S. data suggests that even this target may be too generous. In American adults, an LDL cholesterol of 70 mg/dL corresponded to a median ApoB of just 60 mg/dL, well below the European threshold.
Lipoprotein(a)
Lipoprotein(a), often written as Lp(a), is a genetically determined type of LDL particle that promotes both blood clotting and plaque buildup. Your Lp(a) level is largely set by your genes and doesn’t change much with diet, exercise, or most cholesterol medications. That’s precisely why testing it matters: you can’t manage what you don’t know about.
Levels below 30 mg/dL (or below 75 nmol/L) are considered normal. Between 30 and 50 mg/dL is high risk, and above 50 mg/dL is the highest risk category. About 20% of the population has Lp(a) levels above the high-risk threshold. The National Lipid Association now recommends measuring Lp(a) at least once in every adult to help assess cardiovascular risk. Because the level is genetic and largely stable over your lifetime, one measurement is usually sufficient.
Inflammatory Markers
Some advanced panels include markers of vascular inflammation. High-sensitivity C-reactive protein (hs-CRP) reflects general inflammation throughout the body, including in blood vessel walls, and elevated levels are associated with greater stroke and heart attack risk. A more specific marker called Lp-PLA2 is produced by immune cells inside arterial plaques and reflects active inflammation within blood vessel walls. Elevated Lp-PLA2 can signal that existing plaques are unstable and more likely to rupture. These inflammatory markers add context that pure cholesterol measurements can’t provide.
How the Testing Works
Advanced lipid panels require a standard blood draw, just like a regular cholesterol test. The difference is in how the lab analyzes the sample. The two most common technologies are nuclear magnetic resonance spectroscopy (NMR) and ion mobility analysis. NMR works by detecting signals from lipid molecules that vary depending on the size and number of particles present. Ion mobility converts lipoproteins into a fine spray and sorts them by size using an electric field, producing a direct particle count. Both methods can measure particle number, particle size distribution, and subfraction concentrations across the full range of lipoproteins. A third method, ultracentrifugation, separates particles by density and flotation rate. Each technology has its strengths, and results from different methods aren’t always directly interchangeable.
Who Benefits Most From Advanced Testing
Advanced lipid panels are most valuable when standard numbers don’t tell the full story. That includes people with a family history of early heart disease (before age 55 in men or 65 in women), people with metabolic syndrome or insulin resistance, those with borderline or “normal” LDL cholesterol who still seem to be at elevated risk, and anyone whose doctor is trying to decide whether to start or intensify cholesterol-lowering treatment.
People with type 2 diabetes are a particularly important group. Their LDL cholesterol often looks acceptable, but they frequently carry a high number of small, dense LDL particles. Without advanced testing, that hidden risk goes undetected. The same applies to people with high triglycerides or low HDL, both of which correlate with elevated particle counts that standard LDL cholesterol doesn’t capture.
For Lp(a) specifically, the case for universal screening is strong. Because it’s genetic, testing once gives you a lifetime answer. Children with a family history of premature heart disease, genetically confirmed high cholesterol, or unexplained stroke are also candidates for Lp(a) testing.
Cost and Availability
Advanced lipid panels are widely available through major commercial labs, though they cost more than a standard panel. Insurance coverage varies. Some insurers cover advanced testing when there’s a documented clinical reason, such as a family history of heart disease or an inconsistent risk profile. Others consider it elective. Without insurance, advanced panels typically range from $100 to $400 depending on the specific markers ordered. If cost is a concern, ApoB alone is relatively inexpensive, widely available, and captures much of the additional information an advanced panel provides. Many lipid specialists consider it the single most useful upgrade from a standard panel.